ARS Pharmaceuticals, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ARS Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • ARS Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$21.7M, a 21% decline year-over-year.
  • ARS Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$60.5M, a 16.8% increase year-over-year.
  • ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$67.5M, a 90.1% decline from 2022.
  • ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$35.5M, a 82.6% decline from 2021.
  • ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$19.5M, a 40.9% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$67.5M -$32M -90.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$35.5M -$16.1M -82.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$19.5M +$13.5M +40.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$32.9M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.